Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1411 to 1425 of 2186 results for guidelines

  1. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    21 October 2021

  2. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA1074

  3. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

    Medtech innovation briefing
    Published
    11 January 2022

  4. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST26

  5. Self-management:- What is the impact of different early intervention-focused approaches to self-management on outcomes for older people with social care needs and multiple long-term conditions?

    Any explanatory notes(if applicable) Why this is important:- The Guideline Committee highlighted a lack of evidence on the impact of...

    Research recommendation
    Published
    11 December 2015

  6. Management of type 3c diabetes:- What is the most clinically effective and cost-effective insulin regimen to minimise hypo- and hyperglycaemia for type 3c diabetes secondary to pancreatitis?

    3c diabetes is essential to inform future updates of key recommendations in this guideline. National adoption of evidence-based insulin...

    Research recommendation
    Published
    17 December 2018

  7. In people with suspected TB, what is the relative clinical and cost effectiveness of universal andrisk-based use of rapid nucleic acid amplification tests?

    Any explanatory notes(if applicable) Why this is importantThe guideline committee noted that there were 2 possible approaches to using...

    Research recommendation
    Published
    8 November 2019

  8. Components of a mental capacity assessment:- What are the components of an effective assessment of mental capacity to make a decision (for example checklists, memory aids or standardised documentation)?

    the process and outcomes of these assessments are being recorded. The guideline committee reviewed the small amount of available...

    Research recommendation
    Published
    18 December 2018

  9. Long-term safety of ovarian stimulation and ovulation induction for women:- Is there an association between ovulation induction or ovarian stimulation and adverse long-term (over 20 years) effects in women in the UK?

    for most causes of infertility. During the course of the review for this guideline update the GDG commented on the paucity of long-term...

    Research recommendation
    Published
    9 June 2015

  10. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    10 August 2021

  11. What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    17 December 2021

  12. HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)

    NICE has developed a medtech innovation briefing (MIB) on HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer .

    Medtech innovation briefing
    Published
    7 November 2017

  13. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  14. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    14 July 2022

  15. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA456